HIV/AIDS Archives - Page 2 of 7

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

By Lynn 2024.02.18

Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies.

Dr. WeipingCai: Long-Acting Antiretroviral Drugs Usher in a New Chapter in AIDS Care

By Lynn 2024.01.25

Infectious Disease Frontier specially invited Dr. Weiping Cai from the Eighth Affiliated Hospital of Guangzhou Medical University, China, to provide insightful comments on this hot research area.

Dr. Heather-Marie Schmidt: WHO Long-Acting PrEP Guidelines and Priority Actions to End HIV Epidemic in Asia

By Mourabit Halima 2024.01.15

Heather-Marie Schmidt BMedSc (Hon), MPH, PhD Dr. Schmidt serves as the Regional Advisor on HIV Testing, Prevention, and Key Populations for the Joint United Nations Programme on HIV/AIDS (UNAIDS) Asia-Pacific Regional Office and the World Health Organization (WHO) Global HIV, Hepatitis, and Sexually Transmitted Infections Program. She is dedicated to developing global guidelines for PrEP (Pre-Exposure Prophylaxis) and PEP (Post-Exposure Prophylaxis) and providing technical assistance to countries, organizations, and communities in the Asia-Pacific region to support the implementation and promotion of PrEP.

Dr. Hongzhou Lu: Focus on the Aging of HIV/AIDS Patients, Intrinsic Capacity Assessment is Imperative!

By Lisa Cui 2024.01.15

In recent years, with the effectiveness of antiretroviral therapy (ART) in suppressing HIV replication, the life expectancy of HIV-infected individuals has significantly increased. At the same time, the trend of aging among HIV/AIDS patients has gradually become a research hotspot in the field. From June 8th to 10th, 2023, the Asia Pacific AIDS and Co-infections Conference (APACC 2023) was held in Singapore. In this issue, we are honored to have Dr. Hongzhou Lu from Shenzhen Third People's Hospital share with us the latest research on the aging of HIV/AIDS patients.

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

By Peter W. PENG 2024.01.15

Dr. Iskandar Azwa Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies. At the APACC 2023 conference, Dr. Iskandar Azwa delivered an insightful presentation on "The Role of Nucleosides in Second-Line HIV Treatment." Our journal had the privilege to conduct an in-depth interview with Dr. Azwa regarding the choices for second and third-line treatment for HIV/AIDS patients.

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

By Mourabit Halima 2024.01.15

Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.

Dr. Dong Xu: Meeting More Patient Needs in HIV Health Management

By Mourabit Halima 2024.01.15

Implementation Science is a relatively new and increasingly recognized field of research. Its purpose is to translate the possibilities outlined in theory into practical applications in the real world, addressing the challenges of implementing validated intervention measures. At the 2023 APACC conference, Dr. Dong Hsu, from the School of Public Health Management and the Global Health Research Center, Southern Medical University, China, delivered an insightful presentation titled "Implementation of Clinical Practice Guidelines". In our interview, Dr. Dong Hsu further elaborated on the definition and research value of Implementation Science and shared his team's research findings in areas such as HIV screening and health management.

Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

By Lisa Cui 2024.01.14

Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya's HIV Immunology Translational Research Program, with her current research focus on the immunopathogenic mechanisms of aging in HIV/AIDS patients and their impact on patient health.

Youth Forum of APACC 2023 | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

By Mourabit Halima 2024.01.14

Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.

IAS 2023 | RESPOND Study: INSTIs Might Indeed be “A Bit Sweet”

By Mourabit Halima 2024.01.14

Integrase strand transfer inhibitors (INSTIs) are associated with weight gain, but this weight gain doesn't harm survival or increase cardiovascular disease (CVD) risk. So, does the weight gain associated with INSTIs lead to a higher risk of diabetes? At the recent 12th International AIDS Society (IAS) HIV Science Conference (IAS 2023), the renowned RESPOND cohort study from Europe and America indicated that INSTIs might increase the risk of diabetes onset. Even after adjustment, the onset risk remains statistically significant.